Allermi Secures $3.5M in Seed Funding to Meet Growing Demand for Customized Approach to Allergy Symptoms

Rhea-AI Summary

Allermi, a telehealth service specializing in customized allergy relief, has secured $3.5 million in seed funding, led by Nelstone Ventures and FourSight Capital Partners. This funding aims to support Allermi's expansion across the U.S., enhancing marketing and product operations. Launched in July 2022 with a $1.25 million pre-seed investment, Allermi has experienced rapid growth, increasing by over 30% month-over-month. The company offers a unique nasal spray tailored to patients' specific allergy symptoms, reporting over 90% patient satisfaction. Additionally, Allermi is providing a free trial for new patients.

Positive

• Secured $3.5 million in seed funding to support expansion.
• Reported over 30% month-over-month growth since launch.
• More than 90% of patients report superior relief from allergies.

Negative

• None.

World’s First Customized Multi-Ingredient Nasal Spray Secures Funding to Support Massive Expansion

SAN FRANCISCO--(BUSINESS WIRE)-- Allermi, a direct-to-consumer telehealth service providing a customized approach to allergy relief, today announced a $3.5M seed round to continue its mission to deliver a personalized solution to allergy care. The round was led by Nelstone Ventures, who twice funded Apostrophe - a direct-to-consumer telehealth service providing customized skincare solutions - and helped lead their nine figure sale to Hims & Hers (NYSE: HIMS). In addition to Nelstone Ventures, FourSight Capital Partners also participated in the round.

World’s First Customized Multi-Ingredient Nasal Spray Secures Funding to Support Massive Expansion. (Graphic: Business Wire)

Allermi was co-founded by Dr. Robert Bocian, an allergist for more than 30 years, associate professor of allergy-immunology at Stanford and inventor of Bocian’s Potions, the world’s first custom approach offered by Allermi that combines and adjusts the doses of multiple clinically-proven medications into one nasal spray bottle to address patients’ specific symptoms.

Allermi launched in California last July with a $1.25M pre-seed round led by Lucas Venture Group and has been growing rapidly over 30% month-over-month. Today, Allermi is available across 28 states nationwide. The seed funding will be used to continue national expansion; build and scale business, marketing and product operations; and enlarge marketing channels to meet the growing demand.

“There are approximately 110 million Americans that suffer from nasal congestion and rhinitis. With a custom combination of the right medications at the right dosage, millions of rhinitis sufferers can now achieve far superior relief compared to one-size-fits-all options at the drugstore,” said Co-Founder and CEO Shani Bocian. “This recent funding will allow us to continue innovating our customized solution and make it accessible to allergy sufferers nationwide.”

Despite an abundance of over-the-counter treatments and billions of dollars spent per year, only 30% of allergy sufferers are satisfied with available allergy medications. Allermi provides a personalized solution with over 90% of patients reporting superior relief.

"We first met the Allermi team nearly a year ago and were intrigued by their approach to improving patient care for rhinitis and allergy sufferers through their customized solutions and telemedicine offering,” said Rich Nelson, Founder & Managing Director of Nelstone Ventures. “Since then, we have been very impressed with all that CEO Shani Bocian and the rest of the team have accomplished and are very excited to partner with them as they enter their next phase of growth and expansion.”

After completing an online questionnaire that is then evaluated by an Allermi physician, patients are prescribed a customized nasal spray containing up to four active medication ingredients, combined and dosed for each patient’s unique symptoms and severity.

Delivered by mail on a monthly or on-demand basis, each Allermi patient receives a personalized treatment plan, along with access to a dedicated care team which patients can contact for ongoing support.

Allermi is currently available to residents 18 or older in 28 states including: Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois, Iowa, Kentucky, Massachusetts, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Mexico, New York, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Vermont and Washington.

For a limited time, Allermi is offering a free one-month trial to new patients. To learn more and sign up, please visit www.allermi.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230316005335/en/

Christian Liu

christian@allermi.com

650.332.4535

Source: Allermi

FAQ

What is Allermi's recent funding announcement?

Allermi announced a $3.5 million seed funding round to support its expansion and marketing efforts.

How much has Allermi grown since its launch?

Allermi has experienced over 30% month-over-month growth since its launch in July 2022.

What unique treatment does Allermi offer?

Allermi provides a customized nasal spray that combines multiple active ingredients tailored to individual patient needs.

What percentage of Allermi patients report satisfaction?

Over 90% of Allermi patients report superior relief from their allergy symptoms.

Is Allermi offering any promotions for new patients?

Yes, Allermi is currently offering a free one-month trial for new patients.